Furthermore, an increase of 1 SD of NUDT5 methylation was associated with 4% lower risk of prostate cancer (OR: 0.96, 95% CI: 0.95–0.98, PSMR = 1.15 × 10−5) (Fig. 3). Here, NUDT5 is linked to prostate carcinoma.